VSWA
TEVA icon

Vontobel Swiss Wealth Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Vontobel Swiss Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$276K Buy
+27,895
New +$295K 0.14% 73

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Vontobel Swiss Wealth Advisors's TEVA Position: Q2 2021 in Review

Vontobel Swiss Wealth Advisors opened a new position in Teva Pharmaceutical Industries Limited (TEVA) in Q2 2021: 27,895 shares worth $276K. The stake represents 0.14% of the portfolio and ranks #73 among its holdings.

440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

  • Vontobel Swiss Wealth Advisors held 27,895 shares of Teva Pharmaceutical Industries Limited worth $276K as of Q2 2021.
  • Teva Pharmaceutical Industries Limited was a new Vontobel Swiss Wealth Advisors position in Q2 2021.
  • Teva Pharmaceutical Industries Limited made up 0.14% of Vontobel Swiss Wealth Advisors's portfolio in Q2 2021, its #73 holding.
  • 440 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2021.

Based on Vontobel Swiss Wealth Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.